Number of Shares and Votes in Orexo

UPPSALA, Sweden, Jan. 31, 2018 /PRNewswire/ --

The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs.

Today, the last trading day of the month, there are in total 35,125,456 shares, whereof 34,560,456 are ordinary shares and 565,000 class C shares and 34,616,956 votes in the company.

For further information, please contact:

Orexo AB (publ.)

About Orexo

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees was approx. 100. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.

This information is information that Orexo AB (publ.) is obliged to make public in accordance with the Swedish Financial Instruments Trading Act. The information was submitted for publication at 6.15 pm CET on January 31, 2018.

This information was brought to you by Cision http://news.cision.comhttp://news.cision.com/orexo/r/number-of-shares-and-votes-in-orexo,c2442454

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-orexo-300591282.html

SOURCE Orexo